Overview

Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, two-arm, parallel-group, single-dose study.
Phase:
Phase 1
Details
Lead Sponsor:
Celltrion
Treatments:
Trastuzumab